ClinicalTrials.gg
RecruitingNCT07206758Updated May 28, 2026

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

A Phase 1 interventional study of SHR-2173 Injection in Immune Thrombocytopenia, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 82 open to participants now, 92 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Planned enrollment
153rd of 167
10 · median 62
Started
2025
with 26 others
Phase 1
20 of 185
11 open now
Primary completion
2026-06
later than 40 of 91 live
Registered
165th of 185
by date

Among the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 153rd largest by planned enrollment of the 167 interventional ones that give a count, is one of 27 that started in 2025, is one of 20 in phase 1, reaches primary completion later than 40 of the 91 other live ones, and was the 165th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

82 of the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

76 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety and tolerance of multiple subcutaneous injections of SHR-2173 in ITP patients

03

Conditions studied

  • Immune Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must fully understand the trial content, procedures, and potential adverse reactions, and voluntarily sign a written form (ICF).
  2. Age at signing the ICF must be ≥ 18 years (including the boundary value), regardless of gender.
  3. Confirmed diagnosis of primary ITP for at least 3 months at screening.
  4. Previous treatment with .
  5. At the last ITP treatment, participants experienced loss of remission, no remission, relapse after remission, or intolerance.
  6. count \<30×10⁹/L at screening with clinical assessment indicating treatment necessity
  7. Participants must have adequate organ function
  8. Clinically stable condition with World Health Organization (WHO) bleeding scale grade 0-1
  9. Female participants of or male participants with fertile partners must refrain from sperm/ova donation from ICF signing until 12 weeks after last dose and agree to protocol-specified measures

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of secondary thrombocytopenia or concomitant hemolytic anemia
  2. Received transfusion, whole blood transfusion, plasma exchange, or any other emergency treatment drugs within 14 days prior to the first infusion of SHR-2173
  3. Received (other than ) such as Janus kinase [JAK] inhibitors or Bruton tyrosine kinase [BTK] inhibitors within either 5 times the drug elimination half-life or 14 days prior to the first infusion of SHR-2173 (whichever is longer)
  4. Previous treatment with SHR-2173
  5. Screening or activated partial thromboplastin time outside the normal range; concurrent coagulation disorders and/or receiving antiplatelet or anticoagulant medications (e.g., warfarin, clopidogrel, novel oral anticoagulants), except for low-dose acetylsalicylic acid
  6. History of any thrombotic or embolic events within 12 months prior to the first administration, or clinical symptoms and history suggesting thrombophilia
  7. Current life-threatening bleeding (related to thrombocytopenia) or expected to require emergency treatment within one week after randomization
  8. Active viral, bacterial, or other infections (including tuberculosis [TB]) requiring systemic treatment at screening, or SARS-CoV-2 infection during screening, or history of recurrent infections
  9. Received live or attenuated within 8 weeks prior to the first administration of SHR-2173, or planned to receive live/attenuated vaccinations during the trial
  10. Received live or attenuated live vaccines within 8 weeks prior to the first administration of SHR-2173, or planned to receive live/attenuated vaccinations during the trial
  11. Diagnosis of myelodysplastic syndrome; history of or current within 5 years prior to screening (except for cured non-melanoma skin cancer, in situ carcinoma [e.g., cervical, breast, bladder, prostate cancer], and cancers in complete remission for at least 5 years with no evidence of recurrence)
  12. Previous splenectomy
  13. Previous allogeneic stem cell or organ transplantation (except for corneal transplantation ≥ 3 months prior to screening); known or suspected history of immunosuppression
  14. Planned surgery during the dosing period
  15. Any severe and/or unstable pre-existing medical, psychiatric, or other conditions that the investigator judges may interfere with patient safety, obtaining , or compliance with study procedures
  16. Allergic constitution (e.g., allergies to two or more drugs, foods, or pollens) or known (immediate or delayed) or atopic reactions to the study drug (including , monoclonal antibodies)
  17. Concurrent participation in other studies within either 30 days prior to enrollment or 5 half-lives of the investigational drug (whichever is longer)
  18. Females who are lactating or pregnant (positive serum or urine β-human chorionic gonadotropin [hCG]) at screening or on Day 1 of Week 1 prior to administration
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    SHR-2173 Injection

    Drug: SHR-2173 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence of adverse events (AE) and serious adverse events (SAE) and adverse events of special concern (AESI)

    Time frame: About in the ninth month

  2. The severity of adverse events (AE) and serious adverse events (SAE) and adverse events of special concern (AESI)

    Time frame: About in the ninth month

  3. Changes in abnormal indicators in laboratory inspection

    Time frame: About in the ninth month

Secondary outcomes

  1. Percentage of subjects achieving remission response at week 13 of the treatment period

    Time frame: About in the fourth month

  2. Percentage of subjects achieving remission response at week 25 of the treatment period

    Time frame: About in the sixth month

  3. Percentage of participants achieving remission response at any time during the treatment period

    Time frame: About in the ninth month

  4. Proportion of participants achieving confirmed remission after SHR-2173 injection treatment

    Time frame: About in the ninth month

  5. Time from first SHR-2173 injection treatment to confirmed remission

    Time frame: About in the ninth month

  6. Duration from first confirmed remission to date of remission loss

    Time frame: About in the ninth month

  7. Number and severity of bleeding events

    Time frame: About in the ninth month

  8. Percentage of participants requiring rescue therapy

    Time frame: About in the ninth month

  9. Serum concentration of SHR-2173

    Time frame: About in the ninth month

  10. Anti-SHR-2173 antibodies

    Time frame: About in the ninth month

  11. Serum immunoglobulin levels

    Time frame: About in the ninth month

  12. Count and percentage of B cells and subsets in peripheral blood

    Time frame: About in the ninth month

07

Study locations

1 of 1 sites recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
    Recruiting
    • Heng Mei · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jun 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Oct 3, 2025
StartActual
Nov 12, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Nov 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07206758
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Nov 12, 2025
Primary completion
Jun 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
May 28, 2026

Study contacts

Junye Xiong
Contact
junye.xiong@hengrui.com
0518-82342973
Zuxiang Jin
Contact
zuxiang.jin@hengrui.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-2173

Start the discussion